Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience

Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience

Abstract Background There is no clear data on the optimal duration of treatment with anti-interleukin-1 drugs in colchicine-resistant familial Mediterranean fever patients, as well as on the dose interval. This study aimed to assess patients whose canakinumab dose interval was adjusted according to...

Full description

Bibliographic Details
Main Authors: Gülşah Kavrul Kayaalp, Şengül Çağlayan, Fatma Gül Demirkan, Vafa Guliyeva, Gülçin Otar Yener, Kübra Öztürk, Ferhat Demir, Semanur Özdel, Mustafa Çakan, Hafize Emine Sönmez, Betül Sözeri, Nuray Aktay Ayaz
Format: Article
Language:English
Published: BMC 2023-11-01
Series:Pediatric Rheumatology Online Journal
Subjects:
Familial Mediterranean Fever
Canakinumab
Anti IL-1
Online Access:https://doi.org/10.1186/s12969-023-00925-5

Internet

https://doi.org/10.1186/s12969-023-00925-5

Similar Items